GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Briacell Therapeutics BCT.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

5.20

-6.64%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$26.3m

FY2016FY2025

Free cash flow

−$28.2m

FY2016FY2025

Shareholders' equity

$18.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Research and development$21.3m$27.2m$15.3m$8.0m$942,621$2.1m$3.5m$2.2m$1.5m$677,100
Operating income−$27.2m−$33.3m−$23.3m−$15.3m−$5.0m−$3.4m−$4.5m−$3.6m−$2.3m−$1.6m
Net income−$26.3m−$4.8m−$20.3m−$26.8m−$306,923−$3.5m−$4.1m−$3.9m−$2.3m−$1.6m
Diluted earnings per share-62.19-43.68-194.96-259.82-3.02-4.57-6.08-1,077.35-923.13-77.41

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$22.0m$5.9m$27.2m$42.6m$41.6m$459,800$391,423$2.1m$1.5m$782,178
Cash and short-term investments$18.0m$862,100$21.3m$41.0m——————
Total liabilities$3.8m$8.3m$30.9m$32.2m$560,515$3.6m$997,724$1.3m$791,178$45,480
Debt————$18,620—$283,915$1.0m——
Shareholders' equity$18.0m−$2.4m−$3.8m$10.3m$41.0m−$3.2m−$606,301$882,283$670,013$736,699
Shares outstanding0m0m0m0m0m1m1m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$28.2m−$24.1m−$23.7m−$12.5m−$5.6m−$907,083−$3.0m−$3.6m−$1.4m−$1.1m
Capital spending—−$456,800————————
Free cash flow−$28.2m−$24.6m−$23.7m−$12.5m−$5.6m−$907,083−$3.0m−$3.6m−$1.4m−$1.1m

Latest quarters

By quarter end

Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024
Operating income−$8.3m−$8.6m−$6.3m−$7.2m−$5.2m−$5.8m−$9.2m−$9.8m
Net income−$8.2m−$8.1m−$6.1m−$6.3m−$5.8m−$1.2m$1.7m−$11.0m
Diluted earnings per share-4.35-9.23-16.40-23.31-32.65-10.1516.14-103.23
Cash from operations−$7.0m−$8.0m−$7.0m−$5.0m−$6.0m−$4.0m−$5.0m−$7.0m
Total assets$13.1m$21.6m$17.0m$9.4m$10.4m$5.9m$6.2m$12.0m
Cash and short-term investments$10.2m$17.9m$12.5m$5.0m$5.8m$862,100$935,700$6.2m
Shareholders' equity$10.0m$17.9m$12.4m$3.6m$4.0m−$2.4m−$6.0m−$8.1m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income21.2%51.2%35.7%
Net income-0.7%49.3%26.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-0.1-0.3-0.4-0.3-38.6-9.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 26 Aug 2025
  • 10-to-1 reverse split · 25 Aug 2025
  • 15-to-1 reverse split · 29 Jan 2025
  • 1-to-1 reverse split · 5 Sept 2023
  • 300-to-1 reverse split · 2 Jan 2020
  • 3.25-to-1 reverse split · 3 Dec 2014

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.